Potential drug-drug and drug-disease interactions in well-functioning community-dwelling older adults. 2017

J T Hanlon, and S Perera, and A B Newman, and J M Thorpe, and J M Donohue, and E M Simonsick, and R I Shorr, and D C Bauer, and Z A Marcum, and
Division of Geriatrics, Department of Medicine, School of Medicine, Pittsburgh, PA, USA.

OBJECTIVE There are few studies examining both drug-drug and drug-disease interactions in older adults. Therefore, the objective of this study was to describe the prevalence of potential drug-drug and drug-disease interactions and associated factors in community-dwelling older adults. METHODS This cross-sectional study included 3055 adults aged 70-79 without mobility limitations at their baseline visit in the Health Aging and Body Composition Study conducted in the communities of Pittsburgh PA and Memphis TN, USA. The outcome factors were potential drug-drug and drug-disease interactions as per the application of explicit criteria drawn from a number of sources to self-reported prescription and non-prescription medication use. RESULTS Over one-third of participants had at least one type of interaction. Approximately one quarter (25·1%) had evidence of had one or more drug-drug interactions. Nearly 10·7% of the participants had a drug-drug interaction that involved a non-prescription medication. % The most common drug-drug interaction was non-steroidal anti-inflammatory drugs (NSAIDs) affecting antihypertensives. Additionally, 16·0% had a potential drug-disease interaction with 3·7% participants having one involving non-prescription medications. The most common drug-disease interaction was aspirin/NSAID use in those with history of peptic ulcer disease without gastroprotection. Over one-third (34·0%) had at least one type of drug interaction. Each prescription medication increased the odds of having at least one type of drug interaction by 35-40% [drug-drug interaction adjusted odds ratio (AOR) = 1·35, 95% confidence interval (CI) = 1·27-1·42; drug-disease interaction AOR = 1·30; CI = 1·21-1·40; and both AOR = 1·45; CI = 1·34-1·57]. A prior hospitalization increased the odds of having at least one type of drug interaction by 49-84% compared with those not hospitalized (drug-drug interaction AOR = 1·49, 95% CI = 1·11-2·01; drug-disease interaction AOR = 1·69, CI = 1·15-2·49; and both AOR = 1·84, CI = 1·20-2·84). CONCLUSIONS Drug interactions are common among community-dwelling older adults and are associated with the number of medications and hospitalization in the previous year. Longitudinal studies are needed to evaluate the impact of drug interactions on health-related outcomes.

UI MeSH Term Description Entries
D008297 Male Males
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents

Related Publications

J T Hanlon, and S Perera, and A B Newman, and J M Thorpe, and J M Donohue, and E M Simonsick, and R I Shorr, and D C Bauer, and Z A Marcum, and
January 2006, Journal of nutrition for the elderly,
J T Hanlon, and S Perera, and A B Newman, and J M Thorpe, and J M Donohue, and E M Simonsick, and R I Shorr, and D C Bauer, and Z A Marcum, and
December 2020, Aging clinical and experimental research,
J T Hanlon, and S Perera, and A B Newman, and J M Thorpe, and J M Donohue, and E M Simonsick, and R I Shorr, and D C Bauer, and Z A Marcum, and
November 2021, Drugs & aging,
J T Hanlon, and S Perera, and A B Newman, and J M Thorpe, and J M Donohue, and E M Simonsick, and R I Shorr, and D C Bauer, and Z A Marcum, and
September 2021, Psychology and aging,
J T Hanlon, and S Perera, and A B Newman, and J M Thorpe, and J M Donohue, and E M Simonsick, and R I Shorr, and D C Bauer, and Z A Marcum, and
January 2016, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society,
J T Hanlon, and S Perera, and A B Newman, and J M Thorpe, and J M Donohue, and E M Simonsick, and R I Shorr, and D C Bauer, and Z A Marcum, and
February 2005, Epilepsia,
J T Hanlon, and S Perera, and A B Newman, and J M Thorpe, and J M Donohue, and E M Simonsick, and R I Shorr, and D C Bauer, and Z A Marcum, and
August 2005, The journals of gerontology. Series A, Biological sciences and medical sciences,
J T Hanlon, and S Perera, and A B Newman, and J M Thorpe, and J M Donohue, and E M Simonsick, and R I Shorr, and D C Bauer, and Z A Marcum, and
October 2018, Journal of clinical medicine,
J T Hanlon, and S Perera, and A B Newman, and J M Thorpe, and J M Donohue, and E M Simonsick, and R I Shorr, and D C Bauer, and Z A Marcum, and
November 2021, The British journal of nutrition,
J T Hanlon, and S Perera, and A B Newman, and J M Thorpe, and J M Donohue, and E M Simonsick, and R I Shorr, and D C Bauer, and Z A Marcum, and
December 2005, Journal of geriatric psychiatry and neurology,
Copied contents to your clipboard!